CLEVELAND, Nov. 1 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(Boston Stock Exchange:CFB), today announced that it has responded to a Request for Information (RFI), issued by the Department of Health and Human Services (DHHS), for medical countermeasures to address chemical, biological, radiological and nuclear (CBRN) threats. This RFI will provide critical input to the DHHS Implementation Plan, with the ultimate goal of acquiring the most appropriate medical countermeasures against the highest priority CBRN threats facing the nation.

There are currently no approved therapeutic treatments to protect first responders from Acute Radiation Syndrome (ARS) or to mitigate ARS in victims of a radiological disaster. Lethal doses of gamma radiation result in significant damage to the gastrointestinal system and hematopoietic (bone marrow) stem and progenitor cells, which may lead to infection and hemorrhage. Damage to these two major biological systems is the major contributing factor to radiation-induced mortality.

Cleveland BioLabs is currently developing two distinct therapies directed at ARS, which have been submitted to the DHHS. The more advanced of these compounds, Protectan CBLB502, provides protection from ARS, if administered within several hours of radiation exposure. In addition, CBLB502 is the first compound of its kind to provide protection from both hematopoietic and gastrointestinal radiation-induced damage. The Company's second compound, Protectan CBLB612, has been shown to provide an extended time frame for protection of the immune system in mouse studies.

Both compounds are able to mitigate the damaging effects of gamma irradiation, suggesting for the first time, that victims of radiation exposure can be effectively treated. Both of these compounds are very stable and ideal for rapid deployment using self-injectable devices.

Dr. Yakov Kogan, Executive Vice President of Cleveland BioLabs commented, "This RFI represents a significant opportunity for both Cleveland BioLabs and the DHHS. To date, there are no effective treatments approved for ARS, and we believe that our compounds represent an important step forward in preparation for any potential radiological disasters. We look forward to working closely with the federal government in the continued development of effective ARS treatments and their deployment to protect both the military and civilian populations."

The initial development of Protectan CBLB502 was supported by grants from the DHHS, through the BioShield Act, and NASA. The development of Protectan CBLB612 has been supported by a grant from the Defense Advanced Research Projects Agency of the Department of Defense.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors."

     The Global Consulting Group
     Rachel Levine
     T: (646) 284-9439